FibroGen, Inc. (KYNB)
NASDAQ · Healthcare
FibroGen, Inc. Operating Income 2020–2025
FibroGen, Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- FibroGen, Inc. operating income for the quarter ending March 31, 2026 was -13.8 M, a 6.75% decrease year-over-year.
- FibroGen, Inc. operating income for the twelve months ending March 31, 2026 was -44.3 M.
- FibroGen, Inc. annual operating income for 2025 was -45.3 M, a 65.38% decrease from 2024.
- FibroGen, Inc. annual operating income for 2024 was -131.0 M, a 51.35% decrease from 2023.
- FibroGen, Inc. annual operating income for 2023 was -269.2 M, a 10.57% decrease from 2022.
- FibroGen, Inc. annual operating income for 2022 was -301.0 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
FibroGen, Inc. Operating Income — FAQ
FibroGen, Inc. (KYNB) operating income over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
What is FibroGen, Inc.'s operating income?
FibroGen, Inc. (KYNB) reported operating income of -$45M for fiscal 2025.
Where can I see KYNB's operating income history?
The chart and table above show FibroGen, Inc.'s operating income by year and by quarter, including the growth rate.